Naturally-occurring proteins have evolved over millions of years to perform specific functions based on their sequences and folded structures. As our understanding of science advanced, researchers began designing proteins from scratch to solve new challenges that modern societies face.
In this episode, we talk to David Baker, director of the Institute for Protein Design at the University of Washington and one of the creators of the RoseTTAFold protein structure prediction tool. We discuss how to design proteins with sequences and structures that impart novel functions and how designed proteins will revolutionize drug development.
To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20th, 2022. Register for the event here.
The Generative Biology Revolution is a special edition podcast series produced by The Scientist’s Creative Services Team.
This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.
Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.